TWI851536B - 治療克羅恩氏病和潰瘍性結腸炎之方法 - Google Patents

治療克羅恩氏病和潰瘍性結腸炎之方法 Download PDF

Info

Publication number
TWI851536B
TWI851536B TW107108166A TW107108166A TWI851536B TW I851536 B TWI851536 B TW I851536B TW 107108166 A TW107108166 A TW 107108166A TW 107108166 A TW107108166 A TW 107108166A TW I851536 B TWI851536 B TW I851536B
Authority
TW
Taiwan
Prior art keywords
patient
weeks
pharmaceutically acceptable
acceptable salt
solid form
Prior art date
Application number
TW107108166A
Other languages
English (en)
Chinese (zh)
Other versions
TW201840318A (zh
Inventor
魯派爾Ｂ 塔克
史提芬 強葛維西
廸 拉希爾達 安那 保拉 馬恰多
安Ｍ 羅賓森
愛立Ｌ 潘根
茉漢姆德 雅斯藍 茉漢姆德
安姆 奧特曼
瓊斯 傑佛瑞Ｖ 艾妮瓊薩
班 庫倫德
艾門Ｄ 艾利恩
湯瑪士Ｂ 柏恰爾得
菲德瑞克 萊斯 諾斯瓊
亞曼德Ｙ 席可
馬修Ｍ 穆罕
賈亞新 賈亞斯
派翠克Ｊ 瑪倫
彼得Ｔ 梅爾
Original Assignee
美商艾伯維有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61750557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI851536(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商艾伯維有限公司 filed Critical 美商艾伯維有限公司
Publication of TW201840318A publication Critical patent/TW201840318A/zh
Application granted granted Critical
Publication of TWI851536B publication Critical patent/TWI851536B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
TW107108166A 2017-03-09 2018-03-09 治療克羅恩氏病和潰瘍性結腸炎之方法 TWI851536B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762469337P 2017-03-09 2017-03-09
US62/469,337 2017-03-09
US201762470565P 2017-03-13 2017-03-13
US62/470,565 2017-03-13
US201762483289P 2017-04-07 2017-04-07
US62/483,289 2017-04-07
US201762593629P 2017-12-01 2017-12-01
US62/593,629 2017-12-01

Publications (2)

Publication Number Publication Date
TW201840318A TW201840318A (zh) 2018-11-16
TWI851536B true TWI851536B (zh) 2024-08-11

Family

ID=61750557

Family Applications (2)

Application Number Title Priority Date Filing Date
TW107108166A TWI851536B (zh) 2017-03-09 2018-03-09 治療克羅恩氏病和潰瘍性結腸炎之方法
TW113126496A TW202517269A (zh) 2017-03-09 2018-03-09 治療克羅恩氏病和潰瘍性結腸炎之方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW113126496A TW202517269A (zh) 2017-03-09 2018-03-09 治療克羅恩氏病和潰瘍性結腸炎之方法

Country Status (9)

Country Link
US (3) US20190046527A1 (cg-RX-API-DMAC10.html)
EP (2) EP4487908A3 (cg-RX-API-DMAC10.html)
JP (3) JP2020510016A (cg-RX-API-DMAC10.html)
CN (2) CN110392572A (cg-RX-API-DMAC10.html)
AU (2) AU2018230500B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019018576A2 (cg-RX-API-DMAC10.html)
MX (2) MX2019010733A (cg-RX-API-DMAC10.html)
TW (2) TWI851536B (cg-RX-API-DMAC10.html)
WO (2) WO2018165581A1 (cg-RX-API-DMAC10.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN116270646A (zh) 2015-10-16 2023-06-23 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) * 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
CN110392572A (zh) * 2017-03-09 2019-10-29 艾伯维公司 治疗克罗恩病和溃疡性结肠炎的方法
US20220002306A1 (en) * 2018-09-29 2022-01-06 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of upadacitinib and preparation method and use thereof
EP3891151A1 (en) * 2018-12-05 2021-10-13 LEK Pharmaceuticals d.d. Crystalline phosphate salt of selective jak1 inhibitor upadacitinib
CN111909160B (zh) * 2019-05-09 2024-05-28 苏州鹏旭医药科技有限公司 一种乌帕替尼盐类化合物及其制备方法
CN110101669A (zh) * 2019-06-11 2019-08-09 南京新酶合医药科技有限公司 一种乌帕替尼颗粒的生产工艺
JP2022549379A (ja) 2019-09-30 2022-11-24 アッヴィ・インコーポレイテッド ウパダシチニブによる脊椎関節炎及び乾癬状態の治療
AU2021303629A1 (en) 2020-07-08 2023-03-09 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of upadacitinib, preparation method therefor, and use thereof
US20240316040A1 (en) * 2020-12-29 2024-09-26 Abbvie Inc. Extended release upadacitinib formulations
CN114380837B (zh) * 2021-12-27 2023-06-30 上海邈金医药科技有限公司 一种具有Janus激酶抑制活性的化合物、包括该化合物的组合物及其应用
MX2024008557A (es) * 2022-01-13 2024-09-11 Abbvie Inc Método de administración de upadacitinib para evitar interacciones farmacologicas y efectos adversos.
CA3248817A1 (en) * 2022-01-20 2023-07-27 Renata Pharmaceutical (Ireland) Limited Extended-release pharmaceutical composition of Upadacitinib
WO2024052820A1 (en) * 2022-09-09 2024-03-14 Intas Pharmaceuticals Ltd. Upadacitinib formulation
US12531141B2 (en) * 2023-01-17 2026-01-20 Children's Hospital Medical Center Model-informed precision dosing systems for treatment of inflammatory bowel disease
WO2025149974A1 (en) * 2024-01-11 2025-07-17 Takeda Pharmaceutical Company Limited Combination therapy with an anti-alpha4beta7 antibody
CN120699157B (zh) * 2025-07-16 2025-12-16 安康市中心医院 一种治疗溃疡性结肠炎的恢复肠屏障功能抗体及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0124299D0 (en) 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
MXPA06013250A (es) 2004-05-14 2007-02-28 Abbott Lab Inhibidores de quinasa como agentes terapeuticos.
CN100381175C (zh) 2004-10-09 2008-04-16 山西中医学院 一种微乳制剂及其制备方法
US7772231B2 (en) 2005-12-29 2010-08-10 Abbott Laboratories Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors
CN101553224A (zh) 2006-10-06 2009-10-07 艾博特公司 新型咪唑并噻唑和咪唑并唑
PL2152250T3 (pl) 2007-05-07 2020-06-15 Evonik Röhm Gmbh Stałe postaci dawkowania zawierające otoczkę dojelitową o przyspieszonym uwalnianiu leku
WO2009005675A1 (en) 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
EP2271317B1 (de) 2008-03-28 2017-04-19 Boehringer Ingelheim International GmbH Verfahren zur herstellung von säurepellets
AU2009257602B2 (en) 2008-06-10 2015-10-08 Abbvie Inc. Novel tricyclic compounds
CN101904814A (zh) 2009-06-04 2010-12-08 上海恒瑞医药有限公司 制备载药乳剂的方法
WO2011013082A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
EP4782062A2 (en) 2009-12-01 2026-07-29 AbbVie Inc. Novel tricyclic compounds
FR2991171B1 (fr) 2012-06-01 2014-05-23 Galderma Res & Dev Procede de preparation d'une composition dermatologique comprenant des oleosomes
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
EP3060234A1 (en) * 2013-10-24 2016-08-31 AbbVie Inc. Jak1 selective inhibitor and uses thereof
US20170266289A1 (en) 2014-08-27 2017-09-21 Abbvie Inc. Topical formulation
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN116270646A (zh) 2015-10-16 2023-06-23 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CA3045666A1 (en) * 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
CN110392572A (zh) * 2017-03-09 2019-10-29 艾伯维公司 治疗克罗恩病和溃疡性结肠炎的方法

Also Published As

Publication number Publication date
AU2018230500B2 (en) 2024-03-07
JP2020510016A (ja) 2020-04-02
JP2026041823A (ja) 2026-03-10
MX2022015499A (es) 2023-01-24
US20210361647A1 (en) 2021-11-25
CN110392572A (zh) 2019-10-29
JP2024009963A (ja) 2024-01-23
TW201840318A (zh) 2018-11-16
US20220233527A1 (en) 2022-07-28
US20190046527A1 (en) 2019-02-14
BR112019018576A2 (pt) 2020-04-14
CA3052873A1 (en) 2018-09-13
WO2022178492A1 (en) 2022-08-25
WO2018165581A1 (en) 2018-09-13
AU2024203642A1 (en) 2024-06-20
TW202517269A (zh) 2025-05-01
AU2024203642B2 (en) 2025-08-21
MX2019010733A (es) 2019-11-01
EP4487908A2 (en) 2025-01-08
US11607411B2 (en) 2023-03-21
CN120661512A (zh) 2025-09-19
EP4487908A3 (en) 2025-01-15
AU2018230500A1 (en) 2019-09-19
EP3592353A1 (en) 2020-01-15

Similar Documents

Publication Publication Date Title
AU2024203642B2 (en) Methods of treating Crohn's disease and ulcerative colitis
US20230058001A1 (en) PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11535625B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US20220273651A1 (en) Methods of treating crohn's disease and ulcerative colitis
US12252494B2 (en) Dosing regimens of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine for treatment of indolent systemic mastocytosis
WO2016100310A1 (en) Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
CA3052873C (en) Use of upadacitinib to treat crohn's disease and ulcerative colitis
HK40123037A (en) Methods of treating crohn's disease and ulcerative colitis
BR122022024891B1 (pt) Composição farmacêutica oral de liberação prolongada uma vez ao dia compreendendo (3s,4r)-3-etil-4-(3h-imidazo[1,2-a]pirrolo[2,3-e]pirazin-8-il)-n- (2,2,2-trifluoroetil)pirroli-dina-1-carboxamida
HK1263380B (en) PROCESS FOR THE PREPARATION OF IMIDAZO[1,2-α]PYRROLO[2,3-E]PYRAZINE COMPOUND
BR112018007677B1 (pt) Hemi-hidrato cristalino do composto (3s,4r)-3-etil-4-(3h-imidazo[1,2-a] pirrolo[2,3-e]pirazin-8-il)-n-(2,2,2-trifluoroetil)pirroli-dina-1-carboxamida
BR122022024919B1 (pt) Hidrato de tartarato cristalino do composto (3s,4r)-3-etil4-(3h-imidazo [1,2-a]pirrolo[2,3-e]pirazin-8-il)-n-(2,2,2-trifluoroetil)pirroli-dina-1-carboxamida